Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study)

Diabetic Medicine

Volumn 25, Issue 2, 2008, Pages 186-193

  Van Den Berg, S W ^a   Jansen, E H J ^a   Kruijshoop, M ^b   Beekhof, P K ^a   Blaak, E ^c   Van Der Kallen, C J ^b   Van Greevenbroek, M M ^b   Feskens, E J M ^a,d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Activity; Oxidation; Paraoxonase 1; Phenotype; Type 2 diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ENZYME VARIANT; GLUCOSE; PARAOXON;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; ENZYME SUBSTRATE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; STATISTICAL SIGNIFICANCE;

ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCOSE INTOLERANCE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHENOTYPE;

EID: 39749135579     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02328.x     Document Type: Article

References (40)

1. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993 104 : 129 135.
2. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000 101 : 2510 2517.
3. Rosen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001 17 : 189 212.
4. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998 139 : 341 349.
5. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 1995 42 : 461 465.
6. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996 14 : 334 336.
7. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998 18 : 1617 1624.
8. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) 2000 98 : 355 363.
9. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995 346 : 869 872.
10. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet 2004 363 : 689 695.
11. Chiu KC, Chuang LM, Chu A, Lu J, Hu J, Fernando S et al. Association of paraoxonase 1 polymorphism with beta-cell function: a case of molecular heterosis. Pancreas 2004 28 : 96 103.
12. Grupping AY, Cnop M, Van Schravendijk CF, Hannaert JC, Van Berkel T, Pipeleers DG et al. Low-density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 1997 138 : 4064 4068.
13. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002 143 : 3449 3453.
14. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004 24 : 816 823.
15. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. Br Med J 1998 317 : 727.
16. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1013 eastern Finnish men. Diabetes Care 1997 20 : 426 428.
17. Salonen JT, Nyyssonen K, Tuomainen TP, Maenpaa PH, Korpela H, Kaplan GA et al. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a 4-year follow-up study in men. Br Med J 1995 311 : 1124 1127.
18. Feskens EJ, Virtanen SM, Rasanen L, Tuomilehto J, Stengard J, Pekkanen J et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995 18 : 1104 1112.
19. Kalmar T, Seres I, Balogh Z, Kaplar M, Winkler G, Paragh G et al. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab 2005 31 : 574 580.
20. Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 2003 88 : 1711 1716.
21. van Dam RM, Boer JM, Feskens EJ, Seidell JC. Parental history of diabetes modifies the association between abdominal adiposity and hyperglycemia. Diabetes Care 2001 24 : 1454 1459.
22. Verschuren WMM, van Leer EM, Blokstra A, Seidell JC, Smit HA, Bueno de Mesquita HB et al. Cardiovascular disease risk factors in The Netherlands. Neth J Cardiol 1993 6 : 205 210.
23. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003 56 : 1163 1169.
24. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999 17 : 151 183.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
26. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999 9 : 745 753.
27. Dassen W, Spiering W, de Leeuw P, Smits P, Dijk WA, Spruijt H et al. Unravelling gene interactions to find the cause of artherosclerosis, a multigenic disease, using an artficial neural network. Comput Cardiol 2001 28 : 373 376.
28. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000 43 : 312 320.
29. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high-density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001 38 : 163 169.
30. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K et al. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000 49 : 1400 1405.
31. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A et al. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 2002 28 : 297 304.
32. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003 23 : 2083 2089.
33. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002 22 : 1329 1333.
34. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991 40 : 277 282.
35. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA et al. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 1998 139 : 131 136.
36. Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999 48 : 623 627.
37. Srinivasan SR, Li S, Chen W, Tang R, Bond MG, Boerwinkle E et al. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. Atherosclerosis 2004 177 : 167 174.
38. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995 15 : 1812 1818.
39. Gurgul E, Lortz S, Tiedge M, Jorns A, Lenzen S. Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines. Diabetes 2004 53 : 2271 2280.
40. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003 52 : 1 8.